Myeloma Treatment in Shanghai Tongji Hospital, International Department
About the clinic
Shanghai Tongji Hospital in Shanghai, China, provides specialized cellular immunotherapy for myeloma. The clinic is a tertiary university hospital affiliated with Tongji University and is known for its hematology expertise. CAR-T therapy for multiple myeloma at this facility typically runs around $250,000–$280,000, depending on the specific protocol and patient needs.
Advanced immunotherapy for myeloma
The hospital operates a leading CAR-T program that has been active since 2014. The medical team has performed over 1,500 cell infusions, making it one of the most experienced centers for this treatment. Patients receive care through a multidisciplinary tumor board. This board includes experts in hematology, radiology, pathology, and nutrition to manage every aspect of the recovery process.
Treatment options
- CAR-T cell therapy. This chimeric antigen receptor T-cell therapy is used for relapsed or refractory multiple myeloma. It shows high response rates by using the patient's own immune cells to target the cancer.
- CAR-NK cell therapy. This chimeric antigen receptor natural killer cell therapy serves as a potential alternative. It may offer lower toxicity compared to traditional cell therapies.
CAR-T therapy package details
The cellular immunotherapy program is designed to cover the critical stages of the procedure within the hospital environment. The estimated cost of $250,000–$280,000 for CAR-T for multiple myeloma generally includes several essential components:
- CAR-T cell infusion. The primary procedure where modified cells are returned to the patient.
- Bridging therapy. Treatment used to stabilize the patient while the CAR-T cells are being manufactured.
- In-patient stay. Hospitalization for monitoring during and after the infusion process.
- Follow-up care. Medical observation to manage side effects and track the response to therapy.
Please note that travel, local accommodation, and pre-treatment chemotherapy are typically not included in the standard price. To learn more about the program at Shanghai Tongji Hospital, you may request a consultation on Bookimed.
Highlights
Get a free consultation
Individual treatment program and cost estimate
Average answering time – 5 minutes
Accepted payment methods
View more information
Special offers
Treatments prices in the clinic
| treatment | Price | |
|---|---|---|
| CAR-T for Multiple Myeloma | $250000 - $280000 | |
| CAR T-cell therapy | Price on request | |
| CAR-T for DLBCL | Price on request | |
| CAR-T for Pediatric ALL | Price on request | |
| Bone marrow transplantation | Price on request | |
| Chemotherapy | Price on request |
Clinic Doctors
How are we doing?
Licences
Shanghai Tongji Hospital, International Department: more details about the clinic
Shanghai Tongji Hospital (Shanghai Tongji Hospital), affiliated with Tongji University, is a major public tertiary hospital in Shanghai and one of China’s leading centers for hematology and blood cancer treatment, including lymphoma, leukemia, and multiple myeloma. The Hematology Department and Blood-Tumor Clinical Research Center specialize in advanced cellular immunotherapy, including CAR-T and CAR-NK therapies.
The hospital established its CAR-T program in 2014 and has since performed more than 1,500 CAR-T cell infusions, making it one of the most experienced centers in this field. Over years of clinical development, the team has built a standardized treatment pathway covering patient selection, cell preparation, bridging therapy, infusion, and long-term follow-up. Reported outcomes include a 3-month complete remission rate of approximately 87.5% in lymphoma patients.
For high-risk and refractory cases, the hospital has developed combination approaches such as CAR-T based therapies integrated with additional treatment strategies, improving long-term remission outcomes in selected patient groups. The center has also contributed to the development of innovative approaches such as epigenetic immunotherapy for patients who have not responded to multiple prior treatments.
In lymphoma care, particularly diffuse large B-cell lymphoma (DLBCL), the hospital reports high clinical effectiveness, including strong remission rates in both newly diagnosed and relapsed or refractory cases, significantly improving outcomes compared to conventional therapies.
The hospital is actively involved in global research and clinical innovation, including publications on next-generation CAR-NK cell therapies in leading scientific journals such as Nature Cancer. Its research focuses on improving accessibility, durability, and safety of cellular immunotherapy.
Patient care is organized through a multidisciplinary tumor board involving hematology, radiology, pathology, imaging, nutrition, and psychological support specialists. Advanced diagnostic tools include immunophenotyping for CAR-T eligibility, biopsy techniques, and imaging-guided assessments to ensure precise treatment planning.
Shanghai Tongji Hospital is recognized for its extensive clinical experience in CAR-T therapy, participation in clinical trials, high remission outcomes in lymphoma treatment, and contribution to international research in cellular immunotherapy.
Additional services
Requirements for admission
What treatments do patients most often ask for?
- Myeloma
What procedures do patients have most often?
- Biochemical blood analysis
- Consultation with a hematologist
- Сonsultation with an oncohematologist
- ECG
- Coagulogram
Patient reviews
Wanyang Qiao
Chung Wah, John Chau
Maxim Beatty
Jay Chen
200 Renmin Ave, People's Square, Huang Pu Qu, Shang Hai Shi, China, 200003
Get a free consultation
Individual treatment program and cost estimate
Average answering time – 5 minutes
How it works:
- We find a medical coordinator familiar with the matter
- You get a personal offer with a step-by-step guide and the cost estimate
- We arrange your travel including appointment scheduling and flights booking
- You arrive at the hospital, we support you 24/7